 Connection
Michael Bristow to Pharmacogenetics
This is a "connection" page, showing publications Michael Bristow has written about Pharmacogenetics.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.968 |
|
|
|
-
Fiuzat M, Bristow MR. Pharmacogenetics in heart failure trials. Heart Fail Clin. 2011 Oct; 7(4):553-9.
Score: 0.348
-
Taylor MR, Bristow MR. The emerging pharmacogenomics of the beta-adrenergic receptors. Congest Heart Fail. 2004 Nov-Dec; 10(6):281-8.
Score: 0.215
-
Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF, Felker GM, Liggett SB, O'Connor CM, Bristow MR. Dose Response of ?-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018 08; 11(8):e002210.
Score: 0.140
-
O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and ?1, a2C adrenergic receptor polymorphisms. PLoS One. 2012; 7(10):e44324.
Score: 0.093
-
Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11288-93.
Score: 0.061
-
Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005 Sep; 2(9):475-83.
Score: 0.057
-
Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus?Rhythm in a Genotype-Defined HF?Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
Score: 0.037
-
Taylor MR, Slavov D, Humphrey K, Zhao L, Cockroft J, Zhu X, Lavori P, Bristow MR, Mestroni L, Lazzeroni LC. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics. 2009 Jan; 19(1):35-43.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|